MedTrace Logo

A Study on the Efficacy and Safety of Venetoclax Combined With HAA Regimen in Newly Diagnosed Young AML.

NCT05893472 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2023-06-08

No results posted yet for this study

Summary

The purpose of this study is to investigate the efficacy and safety of the combination of venetoclax and HAA regimen in young, newly diagnosed acute myeloid leukemia patients under the age of 60.

Conditions

Interventions

COMBINATION_PRODUCT

combination of venetoclax and HAA regimen

Using the combination of venetoclax and HAA regimen as induction therapy in young, newly diagnosed adult acute myeloid leukemia patients under the age of 60.

Sponsors & Collaborators

  • Handan Central Hospital

    collaborator OTHER

  • Taian City Central Hospital

    collaborator OTHER

  • Tianjin People's Hospital

    collaborator OTHER

  • Guizhou Provincial People's Hospital

    collaborator OTHER

  • Second Xiangya Hospital of Central South University

    collaborator OTHER

  • Western War Zone General Hospital

    collaborator UNKNOWN

  • ZePing Zhou

    lead OTHER

Principal Investigators

  • DanQi Deng · The Second Affiliated Hospital, Kunming Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
16 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-01
Primary Completion
2024-04-01
Completion
2024-04-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05893472 on ClinicalTrials.gov